Losartan

Introduction Overview

Generic Name

Losartan

Brand Name

Cozaar, Arbli

Dosage Form

Oral tablet (25 mg; 50 mg; 100 mg), oral suspension (10 mg/mL)

Drug Class

Angiotensin II Receptor Blockers (ARBs)

Pharmacokinetics

Absorption:
Losartan is rapidly absorbed following oral administration, with peak plasma concentrations reached within 1 hour. The absolute bioavailability of losartan is approximately 33%, which may be affected by first-pass metabolism in the liver. Food intake has minimal impact on the absorption of losartan, allowing dosing with or without meals. Several clinical pharmacokinetic studies demonstrate that maximum antihypertensive effects are typically observed within 3 to 6 weeks of continuous therapy, corresponding with steady-state plasma concentrations achieved with once-daily dosing.

Distribution:
Losartan exhibits moderate plasma protein binding (~99%) primarily to albumin, which limits free drug available for distribution. It has an apparent volume of distribution of approximately 34 liters. Losartan distributes well into vascular and extravascular tissues, including the heart, kidneys, and vascular smooth muscle, consistent with its site of action. Its active metabolite, EXP3174, is even more potent and has a longer half-life and also binds substantially to plasma proteins. Distribution characteristics support once or twice daily dosing with sustained pharmacologic effect.

Metabolism:
Losartan undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes CYP2C9 and CYP3A4 to form its active metabolite EXP3174 (carboxylic acid derivative). This metabolite contributes significantly to the antihypertensive activity, possessing approximately 10-40 times greater affinity for the angiotensin II type 1 (AT1) receptor than losartan itself. The metabolic pathway involves oxidation and decarboxylation. Hepatic impairment may reduce metabolism, necessitating caution or dose adjustment. Drug interactions involving CYP inhibitors or inducers can alter losartan or metabolite plasma concentrations.

Elimination:
Losartan and its active metabolite are eliminated via both biliary and renal excretion. The elimination half-life of losartan is approximately 2 hours, while the active metabolite has a longer half-life ranging between 6 to 9 hours, supporting once-daily dosing regimens. Approximately 35% of the dose is excreted in urine and about 60% in feces. Renal impairment may modestly affect elimination, thus monitoring and dose adjustments may be necessary in patients with significant kidney dysfunction. Overall, losartan is cleared effectively without significant accumulation in most patient populations.

Dosage Forms

Available Dosage Forms:
Losartan is commercially available as oral tablets and oral suspension preparations, designed to facilitate dose flexibility in adult and pediatric populations. The specific dosage forms include:
- Oral tablet: 25 mg, 50 mg, and 100 mg strengths
- Oral suspension: 10 mg/mL concentration

Dosages for Adults and Adolescents:
- Hypertension: Initial recommended dose is 50 mg orally once daily; dosages can be adjusted up to 100 mg daily based on clinical response. Antihypertensive effects are generally observed within one week, with maximal effects seen at 3 to 6 weeks.
- Stroke Risk Reduction: In hypertensive patients with left ventricular hypertrophy, losartan is used at similar dosing as for hypertension, often titrated to maximum tolerated dose.
- Diabetic Nephropathy: Initial dose of 50 mg orally once daily, titrated to 100 mg daily as needed to reduce progression of kidney disease and proteinuria in type 2 diabetic patients.

Specific Patient Populations:
- Pediatric Hypertension (6 years and older): Initial dose is 0.7 mg/kg orally once daily, up to a maximum dose of 50 mg daily. Dosing forms may include tablets or the oral suspension. Doses above 1.4 mg/kg or 100 mg daily have not been adequately studied in pediatric patients.
- Renal or Hepatic Impairment: Dose adjustment may be necessary depending on severity; caution is advised especially in hepatic impairment due to metabolism by liver enzymes.

Clinical guidelines recommend individualized titration based on blood pressure response and tolerability. The oral suspension formulation allows precise dosing in pediatric and patients with swallowing difficulties, improving adherence and safety.

Mechanism Of Action

Losartan is a selective antagonist of the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor hormone that also stimulates aldosterone secretion, sodium retention, and sympathetic nervous system activation, leading to increased blood pressure and vascular remodeling. By selectively blocking AT1 receptors, losartan inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, thus reducing systemic vascular resistance and blood volume, which together lower arterial blood pressure.

At the molecular level, losartan binds competitively to the AT1 receptor without activating it, preventing angiotensin II from triggering intracellular signaling cascades involving phospholipase C activation, inositol triphosphate generation, and calcium mobilization that mediate vasoconstriction and proliferation of vascular smooth muscle cells. The blockade also limits aldosterone-mediated sodium retention in the kidneys, contributing to blood pressure reduction.

Losartan’s active metabolite, EXP3174, has a significantly higher binding affinity for the AT1 receptor, enhancing the pharmacodynamic effect and prolonging efficacy. This mechanism leads to vasodilation, decreased peripheral resistance, and favorable effects on cardiac remodeling and renal protection. Clinical studies have demonstrated losartan's benefits beyond blood pressure lowering, including reduced incidence of stroke in hypertensive patients with left ventricular hypertrophy and delayed progression of diabetic nephropathy.

Compared to ACE inhibitors, which reduce angiotensin II formation, ARBs like losartan directly block receptor activation, thereby avoiding bradykinin accumulation and associated side effects such as cough. The pharmacologic profile and clinical trials substantiate losartan as a well-tolerated, effective agent for hypertension and renal protection.

Pharmacological Actions

Selective antagonism of angiotensin II type 1 (AT1) receptors leading to vasodilation.
Reduction of peripheral vascular resistance, thereby lowering systemic blood pressure.
Inhibition of aldosterone secretion resulting in decreased sodium and water retention.
Renal protective effects by decreasing glomerular hypertension and proteinuria in diabetic nephropathy.
Prevention of cardiac remodeling and left ventricular hypertrophy associated with hypertension.
Improvement of endothelial function through indirect modulation of renin-angiotensin system.
Lack of significant effect on bradykinin metabolism, minimizing cough and angioedema risk compared to ACE inhibitors.
Prolonged antihypertensive effect owing to active metabolite EXP3174 with high receptor affinity.
Neurohormonal modulation contributing to decreased sympathetic nervous activity.
Reduction of stroke risk in hypertensive patients with left ventricular hypertrophy as evidenced by clinical trials.
Minimal effect on heart rate while effectively reducing blood pressure.
Potentiation of diuretic effects when combined with other antihypertensives without additive renal toxicity.

Therapeutic Or Clinical Uses

Management of hypertension in adults and children aged 6 years and older.
Reduction of risk of stroke in hypertensive patients with left ventricular hypertrophy.
Treatment of diabetic nephropathy with elevated serum creatinine and proteinuria in type 2 diabetes.
Adjunct therapy in heart failure to improve hemodynamics and prevent cardiac remodeling.
Renal protection in hypertensive patients with kidney disease to slow progression of renal impairment.
Use in patients intolerant to ACE inhibitors due to cough or angioedema.
Prevention of cardiovascular morbidity and mortality associated with hypertension.
Blood pressure management in patients requiring combination therapy with other antihypertensives.
Off-label use in certain proteinuric kidney diseases based on renoprotective mechanism.
Potential modulation of inflammatory responses in vascular diseases through RAAS inhibition.
Improvement of endothelial function and arterial compliance in hypertensive patients.
Use in management protocols targeting reduction of left ventricular hypertrophy.

Side Or Adverse Effects

Dizziness and fatigue due to blood pressure lowering effects.
Hypotension, particularly with volume depletion or excessive antihypertensive therapy.
Hyperkalemia caused by aldosterone suppression and potassium retention.
Renal impairment or acute kidney injury in predisposed individuals, especially with dehydration.
Upper respiratory tract symptoms including nasal congestion, sneezing, and sore throat.
Diarrhea and gastrointestinal discomfort.
Back pain reported in some patients during therapy.
Rare allergic reactions including angioedema, rash, and hypersensitivity.
High blood potassium symptoms such as muscle weakness, irregular heartbeat, or numbness.
Orthostatic hypotension causing light-headedness or syncope upon standing.
Potential for increased serum creatinine and blood urea nitrogen, requiring monitoring.
Low blood sugar in diabetic patients may be potentiated.
Fatigue and somnolence observed occasionally.
Rare reports of rhabdomyolysis leading to muscle pain and kidney complications.
Headache and chest pain infrequently reported.

Precautions

Contraindicated during pregnancy due to risk of fetal injury or death, especially in second and third trimesters.
Use cautiously in patients with renal impairment or kidney disease; monitor renal function regularly.
Monitor potassium levels to prevent hyperkalemia, particularly when combined with potassium-sparing diuretics or supplements.
Use with caution in patients with low blood volume or salt depletion to avoid hypotension.
Avoid concomitant use with aliskiren in diabetic patients or those with renal impairment.
Assess liver function prior to initiation and during therapy due to hepatic metabolism.
Careful monitoring required in elderly patients who may be susceptible to hypotension.
Explain to patients the importance of adherence and not discontinuing therapy abruptly to avoid rebound hypertension.
Advise patients to avoid potassium-rich salt substitutes unless recommended by a healthcare provider.
Caution when combined with NSAIDs due to potential renal function impairment and diminished antihypertensive effect.
Patients experiencing muscle pain, tenderness, or weakness should promptly report these symptoms.
Educate patients on signs of angioedema and instruct to seek emergency care if facial or airway swelling occurs.
Advise to rise slowly from sitting or lying position to reduce risk of dizziness and falls.
Monitor blood pressure frequently, especially during dose titration or in dehydration states.
Use with caution in patients with electrolyte imbalances such as hyperkalemia.

Warnings

Losartan is contraindicated in pregnancy; fetal toxicity or death may occur if used during the second and third trimester.
Potential for acute renal failure in volume-depleted or salt-depleted patients, especially with concurrent diuretics.
Hyperkalemia risk increased, particularly with concomitant potassium supplements, potassium-sparing diuretics, or renal impairment.
NSAIDs may reduce antihypertensive effect and increase risk of renal impairment when coadministered with losartan.
Use with aliskiren is contraindicated in diabetic patients and those with renal impairment due to increased risk of adverse outcomes.
Rare but serious risk of rhabdomyolysis necessitating immediate medical attention if muscle pain occurs.
Risk of hypotension and syncope, especially upon initiation or dose increases; patients should be monitored accordingly.
Angioedema as a rare but potentially life-threatening adverse effect requiring prompt discontinuation and treatment.
Use cautiously in patients with bilateral renal artery stenosis due to risk of renal function deterioration.
Discontinuation in patients with heart failure or renal impairment should be gradual and under medical supervision.
Avoid use in patients with known hypersensitivity to losartan or any component of the formulation.
Blood pressure should be monitored frequently in patients undergoing surgery or anesthesia due to potential hypotensive effects.
Elderly patients may be more sensitive to blood pressure lowering effects, requiring closer monitoring.
Patients should be advised against sudden discontinuation to prevent rebound hypertension.
Avoid use during breastfeeding unless benefits exceed potential risks.

Contraindication

Known hypersensitivity or allergy to losartan or any of its components.
Pregnancy, especially during the second and third trimesters due to teratogenicity and fetal harm.
Concomitant use with aliskiren-containing medications in patients with diabetes mellitus.
Use in patients with severe hepatic impairment without appropriate monitoring or dose adjustment.
Patients with a history of angioedema related to previous treatment with ARBs or ACE inhibitors.
Severe bilateral renal artery stenosis due to risk of acute renal failure.
Hypersensitivity reactions necessitate cessation of therapy.
Use with potassium-sparing diuretics or potassium supplements without close monitoring may be contraindicated.
Concomitant use with other agents known to increase serum potassium may be contraindicated in certain populations.
Known hypotension or volume depletion states may warrant contraindication until stabilized.
Avoid if severe hyperkalemia is present prior to initiation.
Contraindicated in children under 6 years of age due to lack of safety and efficacy data.
Use caution or avoid in patients with a history of angioedema not related to ARBs due to potential recurrence.
Concomitant use with nephrotoxic drugs may be contraindicated or require monitoring.
Avoid in patients with uncontrolled electrolyte imbalances.

Drug Interactions

Concomitant use with potassium-sparing diuretics (spironolactone, triamterene, amiloride) increases risk of hyperkalemia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and celecoxib may reduce antihypertensive efficacy and increase risk of renal impairment.
Aliskiren-containing drugs contraindicated in diabetic or renally impaired patients due to increased risk of adverse effects.
Combination with other antihypertensives may have additive hypotensive effects requiring dose adjustments.
Concurrent use with lithium may increase lithium toxicity due to decreased renal clearance.
Rifampin and other CYP3A4 inducers may reduce losartan levels and efficacy.
CYP2C9 inhibitors may increase losartan plasma concentrations, potentially enhancing effects or toxicity.
Diuretics may potentiate the blood pressure lowering effects but may increase risk of electrolyte imbalances.
Simultaneous administration with agents increasing serum potassium (e.g., supplements) requires close monitoring.
Use with other RAAS inhibitors increases risk of hypotension, hyperkalemia, and renal impairment.
Non-potassium sparing diuretics may increase risk of volume depletion exacerbating hypotension.
Drugs affecting renal function may alter losartan pharmacodynamics and pharmacokinetics.
Co-administration with NSAIDs in elderly or volume-depleted patients may precipitate acute kidney injury.
Potentiation of antihypertensive effect observed when combined with calcium channel blockers or beta-blockers.
Azole antifungals may increase losartan concentrations via CYP450 interaction.

Preparations Of The Drug

Oral tablets available in strengths of 25 mg, 50 mg, and 100 mg.
Oral suspension formulation at 10 mg/mL concentration for pediatric or swallowing-impaired patients.
Standard packaging includes blister packs or bottles with child-resistant caps.
Tablets may contain excipients such as lactose, microcrystalline cellulose, magnesium stearate, and others to ensure stability and bioavailability.
Suspension typically requires reconstitution and is supplied with dosing syringes for accurate measurement.
Storage recommended at controlled room temperature away from moisture, heat, and light.
Available as branded formulations (Cozaar, Arbli) and generic equivalents.
Dosage forms designed for once-daily oral administration.
Preparations formulated to ensure appropriate dissolution and bioavailability under physiological conditions.
Packaging designed to maintain drug integrity during transport and storage.
Patient information leaflets with detailed dosing and safety instructions accompany all formulations.
Available through prescription with dosing guides for various indications including hypertension and diabetic nephropathy.
Manufactured under stringent quality control to comply with regulatory standards.
Formulations suitable for use in adults and children aged 6 years and above.
Suspension form intended for patients unable to swallow tablets to facilitate adherence.